Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 15/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25875766 | 0.90 | PLK4 (0.44) | PLK4NTRK1PAK4PIK3CAAURKA | |
| SCHEMBL25875757 | 0.82 | SHMT2 (0.31) | — | |
| SCHEMBL25875778 | 0.79 | PLK4 (0.47) | PLK4NTRK1PAK4 | |
| SCHEMBL25876198 | 0.78 | PLK4 (0.50) | PLK4NTRK1PAK4AURKAAURKB | |
| SCHEMBL28409102 | 0.73 | AURKA (0.55) | AURKAAURKB | |
| SCHEMBL24668009 | 0.73 | AURKA (0.54) | AURKAAURKB | |
| SCHEMBL30250065 | 0.73 | AURKA (0.40) | PAK4AURKAAURKB | |
| SCHEMBL30250129 | 0.73 | AURKA (0.38) | PAK4AURKAAURKB | |
| SCHEMBL30250187 | 0.73 | AURKA (0.54) | AURKAAURKB | |
| SCHEMBL28415530 | 0.73 | AURKA (0.40) | PAK4AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | PLK4 1763/4885NTRK1 29/4885PAK4 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.